A novel, moderately hydrophilic peptide (RYL) with high ACE-inhibitory activity was screened ultrafast via a concept of waste conversion using waste. This novel peptide was screened from silkworm pupa using an Fe-doped porous biocarbon (FL/Z-SE) derived from silkworm excrement. FL/Z-SE possessed magnetic properties and specific selection for peptides due to Fe's dual functions. The selected RYL, which has moderate hydrophilicity (LogP = -0.22), exhibited a comparatively high ACE-inhibitory activity (IC = 3.31 ± 0.11 μM). The inhibitory kinetics and docking-simulation results show that, as a competitive ACE inhibitor, RYL formed five hydrogen bonds with the ACE residues in the S1 and S2 pockets. In this work, both the screening carbon material and the selected ACE-inhibitory peptide were derived from agricultural waste (silkworm excrement and pupa), which offers a new way of thinking about the development of advanced uses of the silkworm byproducts and wastes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jafc.7b04442 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of upper extremity functional capacity in following osteosynthesis for upper limb fractures using a novel method for determining total reachable workspace.
Shoulder Elbow
January 2025
Health Sciences Department, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Objective: This study aimed to assess reachable workspace (RWS) in patients post-osteosynthesis of shoulder, elbow, or wrist fractures and explore correlations with self-reported function and kinesiophobia.
Design: An observational case-control study compared patients with fractures to a control group, utilizing questionnaires and 3D kinematic data.
Participants: The sample included 66 individuals who had undergone osteosynthesis: 21 with shoulder fractures, 10 with elbow fractures, and 22 with wrist fractures.
The simplified GLIM criteria for assessment of malnutrition and its correlation with clinical outcomes in Crohn's disease patients.
Front Nutr
January 2025
Research Center for Metabolic and Cardiovascular Diseases, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Objective: Patients with Crohn's disease (CD) commonly experience malnutrition. The Global Leadership Initiative on Malnutrition (GLIM) criteria, a novel approach to assessing malnutrition, has been validated in some diseases. However, there are limited studies in CD patients.
View Article and Find Full Text PDFlobal egistry of dverse linical vents (GRACE): A Prospective, Multicenter, Observational Cohort Evaluating Complications Associated with Aesthetic Injectables.
J Cutan Med Surg
January 2025
Division of Surgical Research, Head Surgical Epidemiology, McGill University, Montreal, QC, Canada.
Background: A review of Health Canada's post-market surveillance database has revealed that the reporting of adverse events (AEs) following aesthetic injectable treatments is significantly underreported. To increase reporting, investigators have recently developed a novel Electronic Data Capture system: The Global Registry of Adverse Clinical Events (GRACE).
Objective: To identify the incidence of AEs associated with aesthetic injectable treatments.
Classifying tumour infiltrating lymphocytes in oral squamous cell carcinoma histopathology using joint learning framework.
Sci Rep
January 2025
Electrical and Computer Engineering Department, University of Memphis, Memphis, TN, 38152, USA.
Oral squamous cell carcinoma (OSCC) is the most common form of oral cancer, with increasing global incidence and have poor prognosis. Tumour-infiltrating lymphocytes (TILs) are recognized as a key prognostic indicator and play a vital role in OSCC grading. However, current methods for TILs quantification are based on subjective visual assessments, leading to inter-observer variability and inconsistent diagnostic reproducibility.
View Article and Find Full Text PDFPhase II Randomized Trial of BI 730357, a Novel Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis.
J Invest Dermatol
January 2025
Probity Medical Research, Inc., Waterloo, ON, Canada; Alliance Clinical Trials, Waterloo, ON, Canada; Division of Dermatology, University of Toronto School of Medicine, Toronto, ON, Canada.
Trial Design: This two-part, double-blinded trial assessed the truncated retinoic acid-related orphan receptor γ (RORγt) inhibitor BI 730357 in plaque psoriasis.
Methods: Part 1: patients were randomized 2:2:2:2:1 to BI 730357 25, 50, 100, 200 mg, or placebo once daily (qd; fasting conditions); non-responders switched to higher doses. Part 2: a separate patient set was randomized 4:4:1 to BI 730357 400 mg qd, 200 mg twice daily, or placebo (fed conditions).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!